← Back to All Filings

Teva Pharmaceutical Announces Multi-Tranche USD and EUR Senior Notes Offering

Medium SignificanceSeptember 8, 2026 at 7:07:14 AM EDT

TEVA PHARMACEUTICAL INDUSTRIES LTD

$TEVA424B5CIK: 0000818686

Subscribe to track TEVA

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

📋 Teva Pharmaceutical Industries Ltd (TEVA) filed Form 424B5 for a preliminary multi-tranche senior notes offering in USD and EUR guaranteed by the parent company. Net proceeds are intended to fund conditional redemptions of near-term outstanding notes and for general corporate purposes.

Comprehensive Analysis

Offering Overview

Teva Pharmaceutical Industries Ltd. filed a preliminary prospectus supplement (Form 424B5) on September 8, 2026, relating to a multi-tranche senior debt offering through three of its Dutch financing subsidiaries:

  • Teva Pharmaceutical Finance Netherlands II B.V.: Senior Notes due 2033 (EUR) and Senior Notes due 2036 (EUR)
  • Teva Pharmaceutical Finance Netherlands III B.V.: Senior Notes due 2034 (USD) and Senior Notes due 2037 (USD)
  • Teva Pharmaceutical Finance Netherlands IV B.V.: Senior Notes due 2032 (USD)

All notes will be fully and unconditionally guaranteed on a senior unsecured basis by Teva Pharmaceutical Industries Limited.


Use of Proceeds & Debt Refinancing

The net proceeds from the offering, along with cash on hand, are slated for:

  1. Conditional Redemptions: Refinancing existing indebtedness, including:
    • Full redemption of outstanding 6.750% Senior Notes due 2028 (USD)
    • Full redemption of outstanding 7.875% Sustainability-Linked Senior Notes due 2029 (USD)
    • Full redemption of outstanding 7.375% Sustainability-Linked Senior Notes due 2029 (EUR)
    • Up to $450 million aggregate principal amount of 4.750% Sustainability-Linked Senior Notes due 2027 (USD)
    • Up to €1.25 billion aggregate principal amount of 4.375% Sustainability-Linked Senior Notes due 2030 (EUR)
  2. Payment of related fees and transaction expenses.
  3. General corporate purposes and potential further debt reduction.

Key Underwriters

  • Active Joint Book-Running Managers: BNP PARIBAS, Citigroup, Goldman Sachs Bank Europe SE, J.P. Morgan
  • Passive Joint Book-Running Managers: BofA Securities, HSBC, Mizuho
Topics:#TEVA#DebtOffering#Bonds#Refinancing#Pharma

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.